Buoyed by Government of India’s emphasis on animal health with a greater push to controland to eradicate Foot and Mouth Disease (FMD) and Brucellosis in animals, Biovet has embarked on a major expansion plan to create one of the world’s largest FMD vaccine facilities in Malur, Karnataka.

 

Biovetintends to increase its vaccine delivery to help small farmers whose livelihood depend on cattle and dairy farming, when agriculture farming becomes difficult for them. Also, Biovetsays that the investments would provide jobs in construction and create new employment opportunities in Malur.

 

Revealing the details Dr. Ella, Founder, Promoter of Biovetsaid, “Expansion of our FMD vaccine facilities to deliver 200 million doses is an important step to increase our contribution to meet the shortage of this vaccine in the country.We are also excited to announce construction of a new Brucella vaccine production facility at the Malur site, which is underway to produce 100 million doses of Brucella vaccine per year.”

 

“Our plant is the first BSL-3PlusAg production facility established in Asia and 2ndin the world,” Dr. Panduranga Rao,Vice President of Biovet said. Our independent production lines for 3 separate serotype FMD viruses, on completion will be the first of its kind in the world. Further, the new facility for Brucella Vaccines will place Biovet, as the world’s largest manufacturer of this vaccine.” Rao added.

 

Biovet is a Technology driven company with several new products in the pipeline, Dr. B Y Sridhara, General Manager, Biovet said, “We have a world-class BSL-3 containment facility for advanced, research, animal testing and challenge studies in Malur. We are also introducing the latest technologies like High Dense Cell Cultures and Perfusion Technology, Hollow Fiber Technology, along with monitoring the production using Supervisory Control and Data Acquisition Systems to fortify our global quality and audit practices.”

The new investment at its existing site in Malur, Karnataka,has been planned to boost the current vaccine manufacturing capacity from 200 to 500 million doses.